Sleep Studies and Polysomnography: What to Expect

Polysomnography (PSG) is the clinical gold-standard test for diagnosing sleep disorders, recording physiological activity across multiple body systems simultaneously during a full night of sleep. This page covers how PSG is structured, what sensors and channels are involved, which conditions prompt its use, and how it differs from simpler alternatives such as home sleep testing. Understanding this process helps patients and clinicians navigate the diagnostic pathway for conditions like sleep apnea, narcolepsy, and movement disorders.

Definition and scope

Polysomnography is a multi-channel diagnostic recording conducted in an accredited sleep laboratory under the supervision of a registered polysomnographic technologist (RPSGT). The American Academy of Sleep Medicine (AASM), which publishes the clinical standards governing sleep medicine practice in the United States, classifies diagnostic sleep studies into four device types. Type I studies — full attended PSG conducted in a laboratory setting — represent the most comprehensive tier, recording a minimum of 7 data channels simultaneously (AASM Scoring Manual).

The core channel set in a standard Type I PSG includes:

  1. Electroencephalography (EEG) — minimum of 6 leads for sleep stage scoring
  2. Electrooculography (EOG) — 2 channels for eye movement detection
  3. Chin electromyography (EMG) — for muscle tone during REM sleep
  4. Airflow — via thermistor and nasal pressure transducer
  5. Respiratory effort — thoracic and abdominal belts
  6. Pulse oximetry — continuous SpO₂ measurement
  7. Electrocardiography (ECG) — single-lead cardiac monitoring
  8. Leg EMG — bilateral tibialis anterior leads for limb movement detection

Additional channels — such as end-tidal CO₂, esophageal pH, or extended EEG montages — are added for specific diagnostic questions. The scope of a PSG is therefore not fixed; it expands based on the suspected diagnosis. The broader regulatory and standards landscape governing sleep medicine practice is outlined at /regulatory-context-for-sleep.

How it works

A standard in-lab PSG follows a defined procedural structure. Patients typically arrive at the sleep center 1–2 hours before their habitual bedtime to allow sensor application, which takes approximately 45–60 minutes. Lights-out time is set as close to the patient's normal sleep time as possible to reduce first-night effect — the well-documented tendency for sleep architecture to shift in unfamiliar environments.

Throughout the night, a technologist monitors all channels in real time from a separate control room, intervening only when sensor displacement or patient distress requires attention. Total recording time targets a minimum of 6 hours of sleep opportunity, though the AASM recommends at least 2 hours of recorded sleep for valid staging.

Post-acquisition, a trained sleep technologist manually scores the recording in 30-second epochs according to the AASM Scoring Manual criteria. Each epoch is assigned a sleep stage — Wake, N1, N2, N3, or REM — and all respiratory, cardiac, and movement events are annotated. A board-certified sleep medicine physician then interprets the scored study and generates a diagnostic report. The apnea-hypopnea index (AHI), defined as the number of apneas and hypopneas per hour of sleep, is the primary metric for obstructing sleep apnea severity classification: an AHI of 5–14 events/hour is mild, 15–29 is moderate, and ≥30 is severe, per AASM criteria.

Common scenarios

PSG is indicated across a range of clinical presentations. The AASM's clinical practice guidelines identify the following as established indications:

The split-night protocol is a resource-efficient variant in which the first half of the night is used for diagnostic PSG and the second half for CPAP titration if OSA is confirmed with an AHI ≥ 40 events/hour during the diagnostic portion. This reduces the total number of laboratory nights required. For patients managing confirmed OSA with positive airway pressure equipment, CPAP and positive airway pressure therapy covers the treatment pathway in detail.

Decision boundaries

The choice between full in-lab PSG and a Type III or Type IV home sleep apnea test (HSAT) is a clinically structured decision, not simply a matter of convenience. HSAT devices record 4–7 channels without EEG, preventing sleep staging; results are expressed as the respiratory event index (REI) rather than AHI, and REI systematically underestimates true AHI because the denominator is recording time, not actual sleep time.

HSAT is appropriate when the clinical suspicion for moderate-to-severe OSA is high and the patient has no significant cardiorespiratory comorbidity, neurological disorder, or suspected non-respiratory sleep pathology. In-lab PSG is required when HSAT results are negative but clinical suspicion remains elevated, when the patient has conditions that reduce HSAT reliability (moderate-to-severe COPD, heart failure, hypoventilation syndromes), or when a non-respiratory diagnosis is on the differential.

Actigraphy — a wrist-worn movement sensor — is a separate modality that documents rest-activity cycles over weeks and is not a substitute for PSG. Its appropriate role is described at actigraphy and sleep tracking. The National Sleep Foundation and the AASM both publish patient-facing resources that map these decision points for clinical and public audiences.

Insurance coverage for PSG in the United States is governed by Medicare Local Coverage Determinations (LCDs), which specify documentation requirements including a physician order, a face-to-face clinical evaluation, and evidence of specific symptoms. Coverage criteria vary by Medicare Administrative Contractor (MAC) jurisdiction.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)